Max von Pettenkofer-Institute, University of Munich, Munich, Germany.
BMC Biotechnol. 2010 Mar 15;10:20. doi: 10.1186/1472-6750-10-20.
The episomal replication of the prototype vector pEPI-1 depends on a transcription unit starting from the constitutively expressed Cytomegalovirus immediate early promoter (CMV-IEP) and directed into a 2000 bp long matrix attachment region sequence (MARS) derived from the human beta-interferon gene. The original pEPI-1 vector contains two mammalian transcription units and a total of 305 CpG islands, which are located predominantly within the vector elements necessary for bacterial propagation and known to be counterproductive for persistent long-term transgene expression.
Here, we report the development of a novel vector pEPito, which is derived from the pEPI-1 plasmid replicon but has considerably improved efficacy both in vitro and in vivo. The pEPito vector is significantly reduced in size, contains only one transcription unit and 60% less CpG motives in comparison to pEPI-1. It exhibits major advantages compared to the original pEPI-1 plasmid, including higher transgene expression levels and increased colony-forming efficiencies in vitro, as well as more persistent transgene expression profiles in vivo. The performance of pEPito-based vectors was further improved by replacing the CMV-IEP with the human CMV enhancer/human elongation factor 1 alpha promoter (hCMV/EF1P) element that is known to be less affected by epigenetic silencing events.
The novel vector pEPito can be considered suitable as an improved vector for biotechnological applications in vitro and for non-viral gene delivery in vivo.
原型载体 pEPI-1 的附加体复制依赖于从组成型表达的巨细胞病毒立即早期启动子 (CMV-IEP) 开始的转录单元,并定向进入源自人β-干扰素基因的 2000bp 长的基质附着区序列 (MARS)。原始的 pEPI-1 载体包含两个哺乳动物转录单元和总共 305 个 CpG 岛,这些岛主要位于细菌繁殖所需的载体元件内,已知对持续的长期转基因表达产生反作用。
在这里,我们报告了一种新型载体 pEPito 的开发,它源自 pEPI-1 质粒复制子,但在体外和体内都显著提高了功效。与 pEPI-1 相比,pEPito 载体的大小显著减小,仅包含一个转录单元和 60%的 CpG 动机较少。与原始的 pEPI-1 质粒相比,它具有显著的优势,包括更高的转基因表达水平和体外更高的集落形成效率,以及体内更持久的转基因表达谱。通过用已知较少受表观遗传沉默事件影响的人巨细胞病毒增强子/人延伸因子 1α 启动子 (hCMV/EF1P) 元件替换 CMV-IEP,进一步提高了基于 pEPito 的载体的性能。
新型载体 pEPito 可被认为适合作为体外生物技术应用和体内非病毒基因传递的改进载体。